This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Rocket Stocks to Buy for a Happy New Year

Wells Fargo is a conventional retail bank. The firm earns the lion's share of its business as a lender and deposit gatherer, a model that had been eschewed by most of the larger U.S. banks heading into the financial crisis of 2008, only to be re-embraced when the dust cleared. 2008 was a big year for Wells Fargo -- it gave the firm an opportunity to acquire Wachovia at fire sale prices, doubling in size and greatly increasing its exposure on the East Coast.

Historically, Wells Fargo has boasted better margins than its peers, the result of access to extremely cheap deposits. That remains the case today, although the firm is augmenting its strategy with more fee-based revenue streams from its wealth management and retirement services arm. That combination should continue to benefit Wells' shareholders -- especially as interest rates start their uphill climb in the next couple of years.

AstraZeneca

Biopharmaceutical maker AstraZeneca (AZN) is one of the biggest drug makers in the world, with a stable of drugs that brings in more than $33.5 billion a year in sales. The firm's patents include top-producing names like Nexium, Crestor, and Symbicort, three drugs that accounted for almost half of AstraZeneca's revenues last year.

While the patent dropoff has been as much a concern for AZN as it has been for other big pharma peers, generics haven't eaten into the firm's sales as much as expected. In the last couple of years, even drugs with recent generic competition have been able to boost their market share thanks to strong marketing campaigns, easing some worries about the patent cliff that AZN has looming on the horizon. That's not to say that investors aren't worried about patent expirations -- AstraZeneca loses protection on some truly key drugs in the next few years -- but the firm's pipeline has hopes of gaining back a lot of that.

It doesn't hurt that the firm has close to $7 billion in cash. That helps to offset $11 billion in debt, and gives the firm the option to make more acquisitions in the next year before AZN gets to the point where leverage is a concern. Meanwhile, the firm has been using its cash to reward shareholders to the tune of 6% a year in dividends. While AZN isn't without its concerns right now, the risks are priced in and the tailwinds aren't.

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs